CA
NZ
UK
AU
IND
US
…
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
ICU Medical Inc makes infusion therapy systems, vascular access devices, needle‑free connectors and related consumables for hospitals and outpatient infusion care.
Long-term growth may be supported by aging populations, rising demand for infusion and oncology treatments, wider adoption of safety-focused devices and steady consumables revenue, making the company attractive for investors seeking exposure to stable healthcare demand.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 3.17M | -66.01M | -78.30M | -114.41M | 123.19M |
| Net income | 0.73M | -117.69M | -29.66M | -74.29M | 103.14M |
| Selling general administrative | 625.21M | 638.76M | 606.69M | 608.35M | 302.58M |
| Gross profit | 819.65M | 824.78M | 739.87M | 697.76M | 491.49M |
| Reconciled depreciation | 200.74M | 219.51M | 228.77M | 235.15M | 89.70M |
| Ebit | 108.55M | 40.53M | 24.43M | -8.70M | 52.38M |
| Ebitda | 326.54M | 42.96M | 253.20M | 226.45M | 142.08M |
| Depreciation and amortization | 217.99M | 2.44M | 228.77M | 235.15M | 89.70M |
| Non operating income net other | - | - | - | - | 0.80M |
| Operating income | 106.95M | 42.96M | 22.82M | -8.70M | 52.38M |
| Other operating expenses | 2123.07M | 2339.08M | 2236.30M | 2283.57M | 1175.03M |
| Interest expense | 105.38M | 106.54M | 102.73M | 66.38M | 0.86M |
| Tax provision | 2.44M | 51.68M | -48.64M | -40.12M | 20.05M |
| Interest income | 10.31M | 10.79M | 7.51M | 4.43M | - |
| Net interest income | -83.03M | -95.75M | -95.22M | -66.38M | -0.86M |
| Income tax expense | 2.44M | 51.68M | -48.64M | -40.12M | 20.05M |
| Total revenue | 2230.03M | 2382.05M | 2259.13M | 2280.00M | 1316.31M |
| Total operating expenses | 712.71M | 781.82M | 717.05M | 701.33M | 350.21M |
| Cost of revenue | 1410.37M | 1557.26M | 1519.25M | 1582.24M | 824.82M |
| Total other income expense net | -103.78M | -108.98M | -101.12M | -105.70M | 70.80M |
| Net income from continuing ops | 0.73M | -117.69M | -29.66M | -74.29M | 103.14M |
| Net income applicable to common shares | - | - | - | -74.29M | 103.14M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 4050.51M | 4203.93M | 4378.44M | 4515.64M | 1880.74M |
| Intangible assets | 633.56M | 740.79M | 870.59M | 982.77M | 188.31M |
| Other current assets | 73.11M | 346.05M | 91.21M | 88.93M | 2.23M |
| Total liab | 1926.68M | 2238.70M | 2255.03M | 2425.71M | 264.71M |
| Total stockholder equity | 2123.82M | 1965.23M | 2123.41M | 2089.93M | 1616.03M |
| Deferred long term liab | - | - | - | 5.16M | 1.49M |
| Other current liab | 265.57M | 299.87M | 228.15M | 218.13M | 97.99M |
| Common stock | 2.47M | 2.45M | 2.41M | 2.40M | 2.13M |
| Capital stock | 2.47M | 2.45M | 2.41M | 2.40M | 2.13M |
| Retained earnings | 690.89M | 690.16M | 807.85M | 837.50M | 911.79M |
| Other liab | - | - | - | 244.71M | 22.10M |
| Good will | 1499.75M | 1432.77M | 1472.45M | 1449.26M | 43.44M |
| Other assets | - | - | - | 104.40M | 106.35M |
| Cash | 307.96M | 308.57M | 254.22M | 208.78M | 552.83M |
| Total current liabilities | 498.86M | 556.18M | 481.84M | 494.56M | 200.78M |
| Current deferred revenue | 33.84M | 30.36M | 31.64M | 30.84M | 12.65M |
| Net debt | 1084.26M | 1333.10M | 1450.49M | 1444.58M | -507.78M |
| Short term debt | 34.67M | 66.69M | 72.02M | 29.69M | 9.01M |
| Short long term debt | 18.75M | 51.00M | 51.00M | 29.69M | - |
| Short long term debt total | 1392.22M | 1641.66M | 1704.72M | 1653.36M | 45.05M |
| Other stockholder equity | 1465.10M | 1412.03M | 1366.23M | 1331.01M | 721.38M |
| Property plant equipment | - | - | - | 713.58M | 468.37M |
| Total current assets | 1177.44M | 1441.98M | 1219.60M | 1235.20M | 1029.81M |
| Long term investments | 131.59M | 3.04M | 3.12M | 3.69M | 4.62M |
| Net tangible assets | - | - | - | -342.10M | 1616.03M |
| Short term investments | - | 1.21M | 0.50M | 4.22M | 14.42M |
| Net receivables | 180.51M | 202.70M | 164.31M | 221.72M | 105.89M |
| Long term debt | 1265.92M | 1531.86M | 1577.77M | 1623.67M | - |
| Inventory | 615.86M | 584.68M | 709.36M | 696.01M | 290.24M |
| Accounts payable | 154.37M | 148.02M | 150.03M | 215.90M | 81.13M |
| Accumulated other comprehensive income | -34.63M | -139.40M | -53.08M | -80.98M | -19.27M |
| Common stock total equity | - | - | - | - | 2.13M |
| Retained earnings total equity | - | - | - | - | 911.79M |
| Treasury stock | - | - | - | - | -0.03M |
| Non currrent assets other | 62.88M | 56.11M | 56.39M | 105.46M | 63.74M |
| Non current assets total | 2859.95M | 2761.95M | 3158.84M | 3280.45M | 850.93M |
| Capital lease obligations | 47.68M | 58.80M | 75.09M | 80.94M | 45.05M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00M | -88.96M | -87.95M | -1909.47M | 4.72M |
| Change to liabilities | - | - | - | 37.47M | 9.48M |
| Total cashflows from investing activities | 122.23M | -88.96M | -87.95M | -1909.47M | -90.69M |
| Net borrowings | -304.49M | -52.15M | -30.65M | 1641.31M | -0.61M |
| Total cash from financing activities | -311.52M | -55.80M | -35.98M | 1637.03M | -16.87M |
| Change to operating activities | - | - | - | -54.22M | -22.75M |
| Net income | 0.73M | -117.69M | -29.66M | -74.29M | 103.14M |
| Change in cash | -0.60M | 54.34M | 45.44M | -344.04M | 156.73M |
| Begin period cash flow | 308.57M | 254.22M | 208.78M | 552.83M | 396.10M |
| End period cash flow | 307.96M | 308.57M | 254.22M | 208.78M | 552.83M |
| Total cash from operating activities | 179.85M | 204.03M | 166.20M | -62.13M | 267.54M |
| Depreciation | 200.74M | 240.86M | 228.79M | 235.15M | 89.70M |
| Other cashflows from investing activities | 210.27M | -10.09M | -8.28M | - | -26.86M |
| Dividends paid | - | - | 9.35M | - | - |
| Change to inventory | -26.25M | 16.83M | -6.08M | -201.09M | 20.82M |
| Change to account receivables | 8.88M | -46.84M | 48.63M | -19.15M | 13.76M |
| Sale purchase of stock | -8.77M | -11.99M | -9.35M | - | 1.04M |
| Other cashflows from financing activities | -311.52M | -2.60M | -87.95M | 1651.30M | -16.26M |
| Change to netincome | - | - | - | 73.76M | 36.13M |
| Capital expenditures | 88.04M | 79.37M | 93.67M | 99.33M | 81.17M |
| Change receivables | - | - | - | - | 13.76M |
| Cash flows other operating | - | - | - | - | -6.37M |
| Exchange rate changes | - | - | - | - | -3.25M |
| Cash and cash equivalents changes | - | - | - | - | 156.73M |
| Change in working capital | -90.04M | -2.57M | -135.60M | -303.73M | 15.04M |
| Stock based compensation | 55.76M | 46.88M | 40.56M | 36.02M | 27.34M |
| Other non cash items | 12.66M | 36.55M | 62.10M | 44.71M | 29.50M |
| Free cash flow | 91.80M | 124.66M | 72.53M | -161.46M | 186.37M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| ICUI ICU Medical Inc |
-1.86 1.14% |
161.92 | 132.10 | 16.58 | 1.80 | 1.83 | 2.28 | 17.30 |
| ISRG Intuitive Surgical Inc |
11.75 2.72% |
443.76 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
4.93 2.40% |
210.00 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
2.08 2.03% |
104.74 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
1.05 0.53% |
198.93 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
951 Calle Amanecer, San Clemente, CA, United States, 92673
949 366 2183
13000
| Name | Title | Year Born |
|---|---|---|
| Mr. Vivek Jain | CEO & Chairman | 1972 |
| Mr. Brian Michael Bonnell | CFO & Treasurer | 1974 |
| Mr. Christian B. Voigtlander | Chief Operating Officer | 1969 |
| Ms. Virginia Ruth Sanzone | Corp. VP, Gen. Counsel, Sec. & Compliance Officer | 1975 |
| Mr. Vivek Jain | CEO & Chairman of the Board | 1972 |
| Mr. Christian B. Voigtlander | Chief Operating Officer | 1968 |
| Ms. Virginia Ruth Sanzone | Corporate VP, General Counsel, Secretary & Compliance Officer | 1975 |
| Mr. Daniel Woolson | President | 1977 |
| Ben Sousa | Chief Information Officer | NA |
| Olivia Barrall | Vice President of Human Resources | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.36%
Communication Services
+0.47%
Consumer Cyclical
+1.34%
Consumer Defensive
+0.87%
Energy
-2.28%
Financial Services
+1.00%
Financials
+0.52%
Healthcare
-0.64%
Industrials
+0.63%
Real Estate
+0.65%
Technology
-0.08%
Utilities
+0.01%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...